Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aknicare Cream is a topical combination product developed by General Topics for the treatment of mild to moderate acne vulgaris. The formulation utilizes a synergistic blend of triethyl citrate and ethyl linoleate, which are hydrolyzed by skin esterases into citric acid and linoleic acid. This process lowers the skin's pH and inhibits the 5-alpha-reductase enzyme, effectively reducing sebum production and creating an environment unfavorable for *Cutibacterium acnes* colonization. The cream also contains GT peptide-10, an antimicrobial peptide that targets acne-causing bacteria, and 0.5% salicylic acid, which provides keratolytic action to prevent pore blockage. Additional components include zinc lactate for its anti-inflammatory and anti-seborrheic properties, and hyaluronic acid to maintain skin hydration and barrier integrity. It is often evaluated as an adjuvant therapy to standard retinoid treatments such as adapalene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aknicare Cream.